IndiaNifty 5024,207.75▼ -0.52%
IndiaBSE Sensex77,472.94▼ -0.24%
IndiaNifty Bank57,783.75▲ +0.47%
IndiaNifty IT30,318.85▼ -1.47%
IndiaNifty Auto29,000.15▲ 0.00%
IndiaNifty Pharma26,632.95▲ +0.26%
IndiaNifty FMCG47,252.90▲ 0.00%
USS&P 5007,675.70▼ -0.02%
USDow Jones53,463.88▼ -0.21%
USNASDAQ26,130.20▼ -0.08%
UKFTSE 10010,888.53▲ +0.02%
JapanNikkei 22566,257.01▲ +0.61%
Hong KongHang Seng25,652.97▲ +0.56%
GermanyDAX26,314.46▲ +0.18%
FranceCAC 408,469.30▲ +0.36%
AustraliaASX 2009,127.80▼ -0.40%
IndiaNifty 5024,207.75▼ -0.52%
IndiaBSE Sensex77,472.94▼ -0.24%
IndiaNifty Bank57,783.75▲ +0.47%
IndiaNifty IT30,318.85▼ -1.47%
IndiaNifty Auto29,000.15▲ 0.00%
IndiaNifty Pharma26,632.95▲ +0.26%
IndiaNifty FMCG47,252.90▲ 0.00%
USS&P 5007,675.70▼ -0.02%
USDow Jones53,463.88▼ -0.21%
USNASDAQ26,130.20▼ -0.08%
UKFTSE 10010,888.53▲ +0.02%
JapanNikkei 22566,257.01▲ +0.61%
Hong KongHang Seng25,652.97▲ +0.56%
GermanyDAX26,314.46▲ +0.18%
FranceCAC 408,469.30▲ +0.36%
AustraliaASX 2009,127.80▼ -0.40%
Invest and Educate
NYQ · USD

Thermo Fisher Scientific Inc

TMO
633.71
▲ 5.56 (+0.89%)
Price Chart
6MO · Daily
2026-03-112026-04-082026-05-052026-06-022026-06-302026-07-282026-08-26438.34488.34538.34588.34633.71
Key Ratios & Fundamentals
Market Cap
217.52B
P/E (TTM)
31.65
Fwd P/E
21.38
P/B
4.13
P/S
4.69
Book Value
142.47
EPS (TTM)
18.59
Fwd EPS
27.51
Div Yield
+0.32%
Beta
0.85
ROE
+13.51%
ROA
+5.13%
D/E
80.58
Current Ratio
1.55
Profit Margin
+15.04%
Op Margin
+18.75%
52W High
643.99
52W Low
435.27
50D Avg
528.79
200D Avg
532.60
Avg Volume
2.25M
Shares Out
369.75M
Sector
Healthcare
Industry
Diagnostics & Research
About Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

SWOT Analysis
Auto-derived from fundamentals
Strengths
  • Healthy net profit margin of 15.0%
  • Strong liquidity (Current Ratio 1.55) — well-covered short-term obligations
  • Large-cap scale — index inclusion, institutional coverage, deep liquidity
Weaknesses
  • No major red flags in reported financials — continue monitoring quarterly results
Opportunities
  • Solid revenue growth of 10.5% YoY
  • Forward P/E of 21.4x is below trailing — market expects earnings growth
  • Positioned in Healthcare — defensive sector, aligned with respective macro cycles
Threats
  • Standard market risks apply — macro cycles, regulatory changes, and competition
Latest News · Thermo Fisher Scientific Inc
10 stories
3 Unpopular Stocks We Find Risky
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
StockStory·15h ago
Eli Lilly Is Pulling Away From the Rest of Healthcare
Its growth profile stands well above major sector peers.
GuruFocus.com·1d ago
Is Avantor a Buy as Revival Progress Faces Persistent Margin Pressure?
AVTR's Revival Program is lifting VWR growth and BMP orders, but margin pressure and soft earnings keep the recovery selective despite a higher 2026 outlook.
Zacks·1d ago
Top Research Reports for Amgen, Thermo Fisher & Pepsi
Amgen, Thermo Fisher and PepsiCo headline today's research, with growth drivers, strategic moves and key risks in focus.
Zacks·2d ago
There are 6 stocks that both hedge funds and mutual funds have as overweight — and SpaceX is one
SpaceX, trading at 93 times next year’s estimated earnings, seems hardly the stock to unite both short-term-focused hedge-fund managers and more long-term-oriented mutual-fund managers.
MarketWatch·2d ago
Medtronic vs. Thermo Fisher: Which Healthcare Turnaround Offers More Upside?
Turnarounds in the healthcare sector do not all look the same. Some companies recover because management executes better, launches stronger products, and improves operations, while others do so because the industries they serve begin improving after prolonged downturns. Medtronic
Insider Monkey·3d ago
Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?
Healthcare investors are often faced with a choice between companies that generate steady growth across diversified businesses and those positioned to benefit from improving industry conditions. Abbott Laboratories (NYSE:ABT) and Thermo Fisher Scientific (NYSE:TMO) represent thos
Insider Monkey·3d ago
Johnson & Johnson vs. Thermo Fisher: Which Healthcare Growth Story Is More Durable?
Healthcare investors looking for long-term growth don’t always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-quality companies that are growing for entirely different reasons. Johnson & Johnson
Insider Monkey·3d ago
Thermo Fisher vs. Intuitive Surgical: Which Premium Healthcare Stock Deserves its Valuation?
Premium healthcare stocks often trade at elevated valuations for very different reasons. Thermo Fisher’s (NYSE:TMO) investment case increasingly depends on whether the life sciences industry is emerging from its post-pandemic slowdown, while Intuitive Surgical (NASDAQ:ISRG) conti
Insider Monkey·3d ago
Thermo Fisher Scientific (TMO) Could Be Fully Valued On Parkinsons Proteomics Progress
Thermo Fisher Scientific (TMO) is drawing investor attention after completing Olink Explore HT proteomic analysis on about 5,500 samples from The Michael J. Fox Foundation’s Parkinson’s Precision Medicine Initiative. See our latest analysis for Thermo Fisher Scientific. The prote
Simply Wall St.·4d ago
Invest & Educate · Data: Yahoo Finance · News: ET · Mint · Moneycontrol
PrivacyTermsEducational use only. Not investment advice.